Expression and activity of matrix metalloproteinases in the uterus of bitches after spontaneous and induced abortion.
Aim of this study was to determine the intrauterine activity of matrix metalloproteinases (MMP)-2 and -9 after cessation of the local effect of progesterone. For this purpose, pregnancy was terminated in 10 bitches at mid-gestation with the progesterone receptor antagonist aglepristone (10 mg/kg body weight, sc, Alizine®; Virbac, France) at two subsequent days (group IRA = induced resorption/abortion). The IRA group was divided into two subgroups (Group I, n = 5, days 25-35 of pregnancy; group II, n = 5, days 36-45). Five further bitches were introduced with beginning abortion (group SRA = spontaneous resorption/abortion). Seven healthy bitches between day 25 and 45 of gestation served as controls. After ovariohysterectomy at the end of abortion and between days 25 and 45 of gestation, respectively, the distribution and activity of collagenases were investigated by immunohistochemistry and gelatin zymography. At placental sites, MMP-2 activity in the endometrium was significantly lower in IRA groups than in the SRA group (33.7 ± 11.8% and 39.3 ± 5.4% vs 52.2 ± 10.2%, p < 0.05); however, MMP-2 expression was lowest in the control group (control: 21.4 ± 6.3%; p < 0.01) and similarly in the myometrium (controls: 13.1 ± 2.5%; p < 0.05). MMP-9 activity was also lower in the endometrium and myometrium of the control group in comparison to SRA and IRA groups (11.8 ± 3.2%; p < 0.01 and 28.4 ± 32.8%; p < 0.05). At interplacental sites, the amount of active collagenases in the myometrium was significantly lower in the control group. It is concluded that the blockade of the biological progesterone effect was associated with an increase in activity of both collagenases.
Kanca
H
H
Faculty of Veterinary Medicine, Department of Obstetrics and Gynaecology, University of Ankara, Ankara, Turkey. Kanca@veterinary.ankara.edu.tr
Walter
I
I
Miller
I
I
Schäfer-Somi
S
S
Izgur
H
H
Aslan
S
S
D000019:Abortifacient Agents / Q000494:pharmacology; D000028:Abortion, Induced / Q000662:veterinary*; D000034:Abortion, Veterinary / Q000378:metabolism*; D000818:Animals; D004285:Dogs; D004717:Endometrium / Q000378:metabolism; D004963:Estrenes / Q000494:pharmacology*; D005260:Female; D015971:Gene Expression Regulation, Enzymologic / Q000502:physiology; D020778:Matrix Metalloproteinase 2 / Q000235:genetics / Q000378:metabolism*; D020780:Matrix Metalloproteinase 9 / Q000235:genetics / Q000378:metabolism*; D011247:Pregnancy
D000019:Abortifacient Agents; D004963:Estrenes; C419063:aglepristone; D020778:Matrix Metalloproteinase 2; D020780:Matrix Metalloproteinase 9